Stock Taper
SCREENER COMPARE ANY 2 STOCKS
CMPX
COMPASS THERAPEUTICS, INC.
NASDAQ
$2.38
▲ UP 0.42% (0.01)

KEY STATISTICS

Market Cap$427.71 M
52w High$6.88
52w Low$1.61
Dividend Yield—
Frequency—
P/E-5.95
Volume2.53M
Shares Out.180.09M

COMPANY

LEADERSHIP

Thomas J. Schuetz
CHIEF EXECUTIVE
Thomas J. Schuetz

COMPENSATION 2026

Salary$630,000
Stock Awards$0
Incentive Plan Pay$0
All Other Comp.$21,000
Total$5,097,150

ABOUT

SECTOR
Healthcare
WENT PUBLIC
April 5, 2021
METHOD OF GOING PUBLIC
SPAC
FULL TIME EMPLOYEES
39

PRICE TARGET

Target High$9.00
Target Low$6.00
Target Median$7.50
Target Consensus$7.50

UPCOMING EARNINGS

DateNov 4, 2026
DayWednesday
Rev. Est.$229.25K
NOV
4
WED

PRICE

$2.38 ▲ UP 0.42% (+$0.01)
$2.34$2.37$2.40$2.439:30 AM10:35 AM11:40 AM12:44 PM1:49 PM2:54 PM3:59 PM2.38

About Compass Therapeutics, Inc.

https://www.compasstherapeutics.com ↗

Compass Therapeutics, Inc. is a Boston-based clinical-stage biotech developing antibody therapeutics for cancer, including CTX-009, CTX-471, and CTX-8371, targeting pathways like Notch, VEGF, CD137, and PD-1/PD-L1.

INDUSTRY

Biotechnology

A PRODUCT COMPASS THERAPEUTICS, INC. IS KNOWN FOR

Tovecimig (CTX-009)
Tovecimig (CTX-009)

Tovecimig, a clinical-stage bispecific antibody targeting DLL4 and VEGF-A, is Compass Therapeutics' lead candidate showing promising Phase 2/3 results for biliary tract cancer, with key survival data expected in late Q1 2026.

COMPETITORS

COMPETITOR
AMGN COMPARE
PFE COMPARE
REGN COMPARE
SMMT COMPARE
XNCR COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
78
LISTED HERE
16
RANKED BY POSITION SIZE
XBI
0.15% · 7.3M
VTS.AX
0.00% · 4.2M
IWM
0.01% · 3.4M
FESM
0.06% · 1.6M
LABU
0.10% · 243.3K
SBIO
0.24% · 243.1K
DFAC
0.00% · 166.3K
BBC
0.74% · 154.5K
GSSC
0.03% · 117.5K
XRSG.L
0.01% · 105.6K
RSSL
0.01% · 62.2K
URTY
0.00% · 5.2K
VIRS
0.03% · 3.2K
AVTM
0.00% · 2.8K
RESM
0.01% · 250
SC0K.DE
0.01% · 0

INSTITUTIONAL OWNERSHIP

SHARES OWNED
66.98%
HOLDERS
221
TOP 12 OF 221 · RANKED BY POSITION SIZE
Tang Capital Management LLC
16.8M sh · $58.84M
Orbimed Advisors LLC
15.2M sh · $80.51M
Suvretta Capital Management, LLC
14.3M sh · $75.69M
Blackstone Inc.
9.8M sh · $34.44M
Vivo Capital, LLC
9.5M sh · $50.5M
Blackrock, Inc.
9.5M sh · $50.29M
Adage Capital Partners Gp, L.L.C.
8.5M sh · $44.89M
Vanguard Group Inc
8.0M sh · $43.22M
Enavate Sciences Gp, LLC
7.8M sh · $41.2M
Bvf Inc/Il
7.8M sh · $41.7M
State Street Corp
6.7M sh · $35.42M
Blackrock Inc.
6.6M sh · $6.61M

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity3
Price To Earnings1
Price To Book3
Overall Score2

INSIDER TRADES

★
OFFICER: GENERAL COUNSEL
Anderman Jonathan
Purchase · 25.0K shares
2026-04-29
★
OFFICER: CHIEF ACCOUNTING OFFICER
Lerner Neil
Purchase · 15.0K shares
2026-04-29
★
OFFICER: GENERAL COUNSEL
Anderman Jonathan
Purchase · 25.0K shares
2026-04-29
★
OFFICER: CHIEF ACCOUNTING OFFICER
Lerner Neil
Purchase · 15.0K shares
2026-04-29

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 4
OVERWEIGHT 1
MARKET OUTPERFORM 1
6 GRADES IN THE LAST 12 MONTHS
Piper Sandler OVERWEIGHT Citizens MARKET OUTPERFORM Canaccord Genuity BUY HC Wainwright & Co. BUY D. Boral Capital BUY Guggenheim BUY

SECTORS PEERS

PEERPRICE
OMER$19.10COMPARE
CRVS$14.58COMPARE
LXRX$2.23COMPARE
MNPR$118.19COMPARE
FDMT$15.00COMPARE
OCGN$1.34COMPARE
BCYC$4.28COMPARE
FULC$3.85COMPARE